Featured Press Releases

Clarivate introduces the new OFF-X™ platform for preclinical and clinical safety intelligence

Clarivate introduces the new OFF-X™ platform for preclinical and clinical safety intelligence

BioCryst shares real-world data highlighting strong adherence and persistence with ORLADEYO® (berotralstat)

BioCryst shares real-world data highlighting strong adherence and persistence with ORLADEYO® (berotralstat)

  • 24 Oct 2024

BioCryst Pharmaceuticals, Inc. announced new real-world comparative research on the use of oral,...

S&E Bio Secures Korea’s First Approval for a Clinical Trial of Exosome-Based Therapy

S&E Bio Secures Korea’s First Approval for a Clinical Trial of Exosome-Based Therapy

30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

Bruker complements fast and cost-effective IR Biotyper® hospital hygiene testing and HAI tracing with NGS reflex testing

Bruker complements fast and cost-effective IR Biotyper® hospital hygiene testing and HAI tracing with NGS reflex testing

Exilby®, a First-in-Class Non-Opioid Treatment for Chronic Low Back Pain, Receives Its First European Marketing Authorization from VERTANICAL; Pivotal U.S. Phase 3 Trial Underway

Exilby®, a First-in-Class Non-Opioid Treatment for Chronic Low Back Pain, Receives Its First European Marketing Authorization from VERTANICAL; Pivotal U.S. Phase 3 Trial Underway

Virax Biolabs CEO James Foster Updates Shareholders Following the Fiscal 2026 Annual Report and Commercial Supply Agreement with Fosun Diagnostics

Virax Biolabs CEO James Foster Updates Shareholders Following the Fiscal 2026 Annual Report and Commercial Supply Agreement with Fosun Diagnostics

  • Virax BioLabs Group Limited
  • 16 Jul 2026
Children

Children's Hospital of Philadelphia Initiative Substantially Increases Naloxone Co-Prescribing When Prescribing Outpatient Opioids

  • Children's Hospital of Philadelphia
  • 16 Jul 2026
Hologic’s Aptima® HPV Test Receives Expanded CE-IVDR Mark to Include Self-Collected Samples for Cervical Cancer Screening

Hologic’s Aptima® HPV Test Receives Expanded CE-IVDR Mark to Include Self-Collected Samples for Cervical Cancer Screening

  • Hologic, Inc.
  • 14 Jul 2026
Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

  • Merck
  • 14 Jul 2026
BioMarin

BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia Accepted by the U.S. Food and Drug Administration

  • BioMarin Pharmaceutical Inc.
  • 13 Jul 2026
FDA Approves Expanded Indication for Octapharma USA

FDA Approves Expanded Indication for Octapharma USA's wilate® for Prophylaxis of von Willebrand Disease in Children Younger Than 6 Years

  • Octapharma
  • 10 Jul 2026
The Digital Pharma Advances Conference 2026

Most Popular
July   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.